Engineered integrin binding peptides
Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (α 5 β 1 ) or vitronectin (α v β 3 and α v β 5 integrins) are disclosed. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [ Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.
1. An integrin binding peptide, comprising
(i) a sequence binding to at least one of α v β 5 integrin, α v β 3 integrin and α 5 β 1 integrin, and
(ii) a knottin protein scaffold, said sequence being comprised in said knottin protein scaffold and being an engineered integrin binding loop of 11 amino acids comprising the sequence RGD, wherein said RGD is in the sequence X 1 X 2 X 3 RGDX 7 X 8 X 9 X 10 X 11 , wherein each X represents any amino acid as provided in (iii), wherein,
(iii) the knottin protein scaffold is EETI-II, and said integrin binding peptide has a sequence at least 90% identical to a peptide of one of SEQ ID NO: 23 through SEQ ID NO: 52, inclusive.
2. The integrin binding peptide of claim 1 having a Kd of not more than 100 nM.
3. The integrin binding peptide of claim 1 where the integrins bound are αv⊖3 and αv⊖5.
4. The integrin binding peptide of claim 1 where the molecular scaffold is a peptide comprising at least three cysteine disulfide linkages and having crosslinked cysteine residues adjacent the engineered integrin binding loop.
5. The integrin binding peptide of claim 4 which is 90% identical to one of (a) peptide 1.5B as set forth in SEQ ID NO: 28, (b) 2.5D as set forth in SEQ ID NO: 49, or (c) 2.5F as set forth in SEQ ID NO: 50.
6. The integrin binding peptide of claim 1 wherein the substantial identity is at least 95% identical to said one of SEQ ID NO: 23 through SEQ ID NO: 52.
7. An integrin binding peptide as recited in claim 1 , in soluble form.
8. The integrin binding peptide of claim 1 having zero substitutions to a peptide of one of SEQ ID NO: 23 through SEQ ID NO: 52, inclusive.
9. A peptide binding to at least one of αv⊖5 integrin, αv⊖3 integrin and α5⊖1 integrin, said peptide consisting of a binding loop portion and a scaffold portion, wherein said scaffold portion is set forth in SEQ ID NO: 19, and wherein, in the binding portion,
X 1 is selected from the group consisting of A, V, L, P, F, Y, S, H, D, and N;
X 2 is selected from the group consisting of G, V, L, P, R, E, and Q;
X 3 is selected from the group consisting of G, A, and P;
X 7 is selected from the group consisting of W and N;
X 8 is selected from the group consisting of A, P, and S;
X 9 is selected from the group consisting of P and R ;
X 10 is selected from the group consisting of A, V, L, P, S, T, and E; and
X 11 is selected from the group consisting of G, A, W, S, T, K, and E.
10. The integrin binding peptide of claim 9 wherein either:
(a) X 1 is P; X 2 is Q; X 3 is G; X 7 is W; X 8 is A; X 9 is P; X 10 is T; and X 11 is S; or
(b) X 1 is P; X 2 is R; X 3 is P; X 7 is N; X 8 is P; X 9 is P; X 10 is L and X 11 is T.